The Innovators

Designing Medicine's Holy Grail: How Small Molecules May Help Repair the Brain and Stop Cancer in Its Tracks

Overview

Naturally occurring biochemicals called growth factor proteins largely dictate who we are as people. They orchestrate embryological development, guide our maturation from infant to adulthood, regulate immune function, direct the ever-changing alterations to our brains that underlie personality and learning, and enable us to repair damage to our bodies or minds. “Effectively and selectively controlling growth factor function is one of the holy grails of medicine,” says Joe Harding, Washington State University professor of physiology and neuroscience.

Too much or too little growth factor action is the hallmark of our most devastating diseases—from cancer, where over-activation of growth factors leads to uncontrolled cell division and the loss of cell adhesiveness associated with metastasis, to neurodegenerative disease where augmented growth factor activity would be helpful in halting degenerative processes and restoring lost mental and motor functions.

But the development of useful, affordable drugs has been difficult. While there have been some notable successes that block specific growth factor systems, these drugs suffer from a lack of specificity, the development of drug resistance, an inability to reach the brain, or exorbitant costs. The ability to activate growth factors with pharmaceuticals has been even less successful, and no FDA-approved drugs are available.

“Our laboratory has developed a technology that targets a process common to many growth factors,” Harding says. “We have successfully built molecules that can either activate or inhibit growth factors. These small molecule drugs are inexpensive to manufacture, highly specific, and can be designed to reach the brain.”

In Harding’s Innovators talk, he will focus on hepatocyte growth factor and its potential to halt and possibly reverse the impact of neurodegenerative diseases.

“We’ve developed a molecule called Dihexa that shows great promise at halting and perhaps reversing the devastating effects of Parkinson’s disease and dementias,” Harding says. “In animals, we are seeing therapeutic effects attributable to a combination of neuro-protection from the offending insult, the generation of new connections among surviving nerve cells, and the production of new nerve cells from stem cells that reside in the brain.”

Harding and his colleagues see potential for this technology to reach far beyond the treatment of neurodegenerative diseases.

“There is a potential here to develop innovative treatments for almost every major human disease,” Harding says, “including cancer, diabetes, and congestive heart failure.”

Dr. Joe Harding is a professor of physiology and neuroscience in the Washington State University College of Veterinary Medicine, Department of Veterinary and Comparative Anatomy, Pharmacology and Physiology. The co-author of over 200 peer-reviewed publications, Dr. Harding is the lead inventor on several patents.

Dr. Harding is the co-founder of M3 Biotechnology, a Seattle-based pharmaceutical company that seeks to create affordable therapies for devastating diseases by strategically partnering with companies and foundations and employing Pacific Northwest talent.

The primary objective in Dr. Harding’s laboratory is to develop pharmaceuticals for the treatment of dementia, cancer, and deficits in wound healing. Through their ongoing investigation of growth factor proteins, Dr. Harding and his colleagues have developed an innovative strategy that shows great promise for treatment of a wide variety of diseases.

Dr. Harding completed his B.S. in chemistry at Allegheny College in 1970 and Ph.D. in chemistry at the University of Delaware in 1974. He was a postdoctoral fellow in neurochemistry with Frank Margolis at Roche Institute of Molecular Biology in 1974-76 and has been at Washington State University since 1976.

Learn more about Dr. Harding’s work on the WSU College of Veterinary Medicine website.

Bell Harbor International Conference Center

2211 Alaskan Way, Pier 66

Seattle, Washington 98121

Bell Harbor Directions

To access Bell Harbor International Conference Center's main entrance:

Inside the garage, go to the fourth floor and walk across the skybridge. Take the elevator or stairs down one level to the third floor and enter Bell Harbor International Conference Center.

Office of Research | Washington State University | PO Box 1030 Pullman, WA 99164-1030 | 509-335-6412